Stocks · Korea
092730
KOSDAQ
Neopharm
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-07 basis
PER13.63x
PBR1.94x
EPS1,779 KRW
BPS12,490 KRW
ROE15.26%
Dividend yield3.09%
DPS750 KRW
Payout ratio42.16%
Returns and 52-week range
1W+1.68%
1M+4.75%
3M+30.45%
6M+38.89%
1Y+32.08%
YTD+27.70%
52W high26,000원
52W low15,590원
From 52W high-6.73%
Financial results (consolidated)
| Period | Revenue | Operating income | Net income | OP margin |
|---|---|---|---|---|
| 2022 | 850억 | 214억 | 170억 | 25.2% |
| 2023 | 971억 | 253억 | 232억 | 26.1% |
| 2024 | 1,190억 | 247억 | 231억 | 20.7% |
| 2025 | 1,322억 | 288억 | 278억 | 21.8% |
| Quarterly | ||||
| 2024 3Q | 262억 | 51억 | 43억 | 19.4% |
| 2024 4Q | 340억 | 67억 | 67억 | 19.6% |
| 2025 1Q | 316억 | 78억 | 71억 | 24.6% |
| 2025 2Q | 320억 | 70억 | 71억 | 21.9% |
| 2025 3Q | 322억 | 68억 | 69억 | 21.0% |
| 2025 4Q | 364억 | 72억 | 68억 | 19.8% |
Company
Address: 대전 유성구 탑립동 928번지
Peers in the same sector
Recent filings
- 2026-08-14반기보고서 (2026.06)
- 2026-05-14분기보고서 (2026.03)
Source: DART (Financial Supervisory Service electronic disclosure)
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.